190 related articles for article (PubMed ID: 8135145)
41. Modulation of interleukin-2-induced macrophage activation in cancer patients by the pineal hormone melatonin.
Lissoni P; Tisi E; Brivio F; Ardizzoia A; Crispino S; Barni S; Tancini G; Conti A; Maestroni GJ
J Biol Regul Homeost Agents; 1991; 5(4):154-6. PubMed ID: 1803863
[TBL] [Abstract][Full Text] [Related]
42. Activities of granulocyte-macrophage colony-stimulating factor and interleukin-3 on monocytes.
Suzuki H; Katayama N; Ikuta Y; Mukai K; Fujieda A; Mitani H; Araki H; Miyashita H; Hoshino N; Nishikawa H; Nishii K; Minami N; Shiku H
Am J Hematol; 2004 Apr; 75(4):179-89. PubMed ID: 15054806
[TBL] [Abstract][Full Text] [Related]
43. [Tumor-induced anemia and markers of inflammation].
Morant R; Bacchus L; Meyer J; Riesen WF
Schweiz Med Wochenschr; 1994 Dec; 124(50):2267-71. PubMed ID: 7809592
[TBL] [Abstract][Full Text] [Related]
44. Effects of cancer chemotherapy on the relation between serum levels of soluble interleukin-2 receptors and CD4/CD8 ratio in patients with solid neoplasms.
Lissoni P; Barni S; Tancini G; Viviani S; Rovelli F; Rescaldani R; Fiorelli G
J Biol Regul Homeost Agents; 1989; 3(3):131-3. PubMed ID: 2560317
[TBL] [Abstract][Full Text] [Related]
45. Monitoring of tumor necrosis factor therapy with neopterin.
Peters KM; Dommaschk J; Grundmann R; Schaadt M; Schicha H
Arzneimittelforschung; 1990 Apr; 40(4):508-10. PubMed ID: 2357253
[TBL] [Abstract][Full Text] [Related]
46. Treatment with GM-CSF and IL-2 in patients with metastatic colorectal carcinoma induced high serum levels of neopterin and sIL-2R, an indicator of immune suppression.
Skog AL; Wersäll P; Ragnhammar P; Frödin JE; Mellstedt H
Cancer Immunol Immunother; 2002 Jul; 51(5):255-62. PubMed ID: 12070712
[TBL] [Abstract][Full Text] [Related]
47. Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission.
Shaw CE; Dunbar PR; Macaulay HA; Neale TJ
J Neurol; 1995 Jan; 242(2):53-8. PubMed ID: 7707089
[TBL] [Abstract][Full Text] [Related]
48. Neopterin serum levels in pancreatic adenocarcinoma.
Manes G; Spada OA; Rabitti PG; Feola B; Misso S; Minerva A; Uomo G
Int J Pancreatol; 1999 Feb; 25(1):31-7. PubMed ID: 10211419
[TBL] [Abstract][Full Text] [Related]
49. [Neopterin and interleukin 2 soluble receptors as biochemical markers of cellular immune response to surgical trauma].
Delogu G; Reale G; Marchei GG; Rezaeieh RH; Casula MA; Reale C; Signore L; Martinelli V
Ann Ital Chir; 1992; 63(3):359-62; discussion 363. PubMed ID: 1444001
[TBL] [Abstract][Full Text] [Related]
50. Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure.
Stasi R; Zinzani L; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Tura S; Papa G
Cancer; 1994 Sep; 74(6):1792-800. PubMed ID: 8082082
[TBL] [Abstract][Full Text] [Related]
51. Disease severity in rheumatoid arthritis: relationships of plasma tumor necrosis factor-alpha, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures.
Beckham JC; Caldwell DS; Peterson BL; Pippen AM; Currie MS; Keefe FJ; Weinberg JB
J Clin Immunol; 1992 Sep; 12(5):353-61. PubMed ID: 1430106
[TBL] [Abstract][Full Text] [Related]
52. Different lymphoid cell populations produce varied levels of neopterin, beta 2-microglobulin and soluble IL-2 receptor when stimulated with IL-2, interferon-gamma or tumour necrosis factor-alpha.
Hofmann B; Bass H; Nishanian P; Faisal M; Figlin RA; Sarna GP; Fahey JL
Clin Exp Immunol; 1992 Jun; 88(3):548-54. PubMed ID: 1606739
[TBL] [Abstract][Full Text] [Related]
53. Elevated serum levels of neopterin in adult patients with polymyositis/dermatomyositis.
Samsonov MY; Nassonov EL; Tilz GP; Geht BM; Demel U; Gurkina GT; Shtutman VZ; Guseva AG; Wachter H; Fuchs D
Br J Rheumatol; 1997 Jun; 36(6):656-60. PubMed ID: 9236675
[TBL] [Abstract][Full Text] [Related]
54. [Markedly elevated serum neopterin levels in patients with hemophagocytic histiocytosis].
Shinmyozu K; Machigashira N; Itoyama T; Maruyama I; Osame M
Rinsho Ketsueki; 1992 Apr; 33(4):545-7. PubMed ID: 1602622
[TBL] [Abstract][Full Text] [Related]
55. Soluble TNF receptors (TNF-sR55 and TNF-sR75) in lung allograft recipients displaying cytomegalovirus pneumonitis.
Humbert M; Roux-Lombard P; Cerrina J; Magnan A; Simonneau G; Dartevelle P; Galanaud P; Dayer JM; Emilie D
Am J Respir Crit Care Med; 1994 Jun; 149(6):1681-5. PubMed ID: 8004330
[TBL] [Abstract][Full Text] [Related]
56. [Cytokines in extracorporeal circulation].
Giordano G; Pignatelli MG; Biancardi L; Castenetto E; Vai M; Cavalli G; Polloni R; Ferro M; Amprimo MC; Roccatello D
Minerva Anestesiol; 1991 Oct; 57(10):1020-1. PubMed ID: 1961455
[No Abstract] [Full Text] [Related]
57. Serum neopterin levels in liver cirrhosis.
Antoniello S; Russo M; Bizzarro A; Auletta M; De Bellis A; Magri P; Russo P; Dell'Aquila A; Cacciatore L
J Biol Regul Homeost Agents; 1989; 3(4):159-62. PubMed ID: 2638148
[TBL] [Abstract][Full Text] [Related]
58. Modulation of macrophage response to interleukin-2 immunotherapy by interleukin-3 in cancer patients.
Lissoni P; Rovelli F; Barni S; Ardizzoia A; Pittalis S; Tisi E; Perlangeli V; Tancini G
Biol Chem Hoppe Seyler; 1992 Dec; 373(12):1217-22. PubMed ID: 1292506
[TBL] [Abstract][Full Text] [Related]
59. Interleukin-2, soluble interleukin-2-receptor, neopterin, L-tryptophan and beta 2-microglobulin levels in CSF and serum of patients with relapsing-remitting or chronic-progressive multiple sclerosis.
Ott M; Demisch L; Engelhardt W; Fischer PA
J Neurol; 1993 Dec; 241(2):108-14. PubMed ID: 8138825
[TBL] [Abstract][Full Text] [Related]
60. [Blood levels of neopterin in patients with liver cirrhosis].
Antoniello S; Di Martino G; Russo M; Bizzarro A; Auletta M; De Bellis A; Cacciatore L
Ann Ital Med Int; 1989; 4(3):167-72. PubMed ID: 2484506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
